# US 2011/0150889 A1 · Haemophilus influenzae type iv pili

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0150889 A1
- Document ID: US20110150889A1
- Status: Published application
- Kind: A1
- Application number: 13/005,166
- Filed: 2011-01-12
- Published: 2011-06-23
- Earliest claimed: 2003-12-23
- Assignees: Nationwide Children's Hospital, Inc.
- Inventors: Lauren O. Bakaletz; Robert S. Munson, JR.
- Web page: https://patentgrep.com/patent/US20110150889A1

## CPC

- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 27/16: Otologicals
- A61P 31/04: Antibacterial agents
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- C07K 14/195: from bacteria
- C07K 14/285: from Pasteurellaceae (F), e.g. Haemophilus influenza
- C07K 16/1242: {from Pasteurellaceae (F), e.g. Haemophilus influenza}
- C12Q 1/689: for bacteria
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- C07K 2319/00: Fusion polypeptide
- Y10S 435/851: Haemophilus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly/disassembly of the structure. The invention also relates to uses of these polynucleotides and/or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.

## Claims

### Claim 1

An isolated polynucleotide comprising a nucleotide sequence encoding an amino acid sequence of any one of: PilA polypeptide SEQ ID NO: 2, PilB polypeptide SEQ ID NO: 4, PilC polypeptide SEQ ID NO: 6, PilD polypeptide SEQ ID NO: 8, ComA polypeptide SEQ ID NO: 10, ComB polypeptide SEQ ID NO: 12, ComC polypeptide SEQ ID NO: 14, ComD polypeptide SEQ ID NO: 16, ComE polypeptide SEQ ID NO: 18, ComF polypeptide SEQ ID NO: 20, PilF polypeptide SEQ ID NO: 22, PilA polypeptide SEQ ID NO: 26, PilA polypeptide SEQ ID NO: 26, PilA polypeptide SEQ ID NO: 28, PilA polypeptide SEQ ID NO: 30, PilA polypeptide SEQ ID NO: 32, PilA polypeptide SEQ ID NO: 34, PilA polypeptide SEQ ID NO: 36, PilA polypeptide SEQ ID NO: 38, PilA polypeptide SEQ ID NO: 40, PilA polypeptide SEQ ID NO: 42, or pilA polypeptide SEQ ID NO: 44.

### Claim 2

An isolated polynucleotide comprising a nucleotide sequence of any one of: pilA SEQ ID NO: 1, pilB SEQ ID NO: 3, pilC SEQ ID NO: 5, pilD SEQ ID NO: 7, comA SEQ ID NO: 9, comB SEQ ID NO: 11, comC SEQ ID NO: 13, comD SEQ ID NO: 15, comE SEQ ID NO: 17, comF SEQ ID NO: 19, pilF SEQ ID NO: 21, pilA SEQ ID No: 25, pilA SEQ ID No: 27, pilA SEQ ID No: 29, pilA SEQ ID No: 31, pilA SEQ ID No: 33, pilA SEQ ID No: 35, pilA SEQ ID No: 37, pilA SEQ ID No: 39, pilA SEQ ID No: 41 or pilA SEQ ID No: 43.

### Claim 3 (depends on 1)

A vector comprising a polynucleotide of claim 1.

### Claim 4 (depends on 1)

An isolated polypeptide comprising an amino acid sequence encoded by a nucleotide sequence of claim 1 or a fragment thereof.

### Claim 5

An isolated polypeptide comprising an amino acid sequence of any one of PilA polypeptide SEQ ID NO: 2, PilB polypeptide SEQ ID NO: 4, PilC polypeptide SEQ ID NO: 6, PilD polypeptide SEQ ID NO: 8, ComA polypeptide SEQ ID NO: 10, ComB polypeptide SEQ ID NO: 12, ComC polypeptide SEQ ID NO: 14, ComD polypeptide SEQ ID NO: 16, ComE polypeptide SEQ ID NO: 18, ComF polypeptide SEQ ID NO: 20, PilF polypeptide SEQ ID NO: 22, PilA polypeptide SEQ ID NO: 26, PilA polypeptide SEQ ID NO: 26, PilA polypeptide SEQ ID NO: 28, PilA polypeptide SEQ ID NO: 30, PilA polypeptide SEQ ID NO: 32, PilA polypeptide SEQ ID NO: 34, PilA polypeptide SEQ ID NO: 36, PilA polypeptide SEQ ID NO: 38, PilA polypeptide SEQ ID NO: 40, PilA polypeptide SEQ ID NO: 42, or pilA polypeptide SEQ ID NO: 44, or a peptide fragment thereof.

### Claim 6 (depends on 5)

A composition comprising a polypeptide or peptide fragment of claim 5 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 5)

An antibody that specifically binds to a polypeptide or peptide fragment of claim 5.

### Claim 8 (depends on 8)

A composition comprising an antibody of claim 8 and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 1)

A method for detecting NTHi bacteria in a biological sample comprising
(a) contacting a polynucleotide of claim 1 or a fragment thereof with a biological sample, and
(b) detecting hybridization of the polynucleotide within the sample,
wherein hybridization indicates the presence of NTHi bacteria.

### Claim 10 (depends on 2)

A method for detecting NTHi bacteria in a biological sample comprising
(a) contacting a polynucleotide of claim 2 or a fragment thereof with a biological sample, and
(b) detecting hybridization of the polynucleotide within the sample,
wherein hybridization indicates the presence of NTHi bacteria.

### Claim 11 (depends on 7)

A method for detecting NTHi bacteria in a biological sample comprising:
(a) contacting an antibody of claim 7 with a biological sample, and
(b) detecting binding of the antibody within the sample, wherein binding indicates the presence of NTHi bacteria.

### Claim 12 (depends on 9)

The method of claim 9 wherein the biological sample is selected from the group consisting of serum, sputum, ear fluid, blood, urine, lymphatic fluid, and cerebrospinal fluid.

### Claim 13 (depends on 5)

A method for eliciting an immune response to NTHi bacteria comprising administering an immunogenic dose of one or more polypeptides or peptide fragments of claim 5 to a patient at risk of NTHi bacterial infection.

### Claim 14 (depends on 1)

A method for eliciting an immune response to NTHi bacteria comprising administering an immunogenic dose of one or more polynucleotides of claim 1 to a patient at risk of NTHi bacterial infection.

### Claim 15 (depends on 14)

The method of claim 14 wherein the polynucleotide is in a plasmid or viral vector.

### Claim 16 (depends on 5)

A method of treating or preventing NTHi bacterial infection comprising administering a molecule that inhibits expression or activity of a polypeptide of claim 5 to an patient in need thereof.

### Claim 17 (depends on 16)

The method of claim 16 wherein the molecule administered to the patient in need is an antisense oligonucleotide.

### Claim 18 (depends on 16)

The method of claim 16 wherein the molecule administered to the patient in need is an antibody.

### Claim 19 (depends on 16)

The method of claim 16 wherein the molecule administered to the patient in need is a small molecule.

### Claim 20 (depends on 16)

The method of claim 16 wherein the NTHi infection is in the middle ear.
